A new breakthrough therapy designation (BTD) for AstraZeneca PLC's Imfinzi (durvalumab) signals FDA's confidence in the promise of the agent in non-metastatic non-small cell lung cancer, a setting earlier in the disease course than the metastatic NSCLC indications FDA has so far granted to immunotherapies.
The BTD is a welcome counterpoint to the disappointing results from the Phase III MYSTIC trial as first-line treatment for...






